NEUROENDOCRINE (NE) TUMORS
Clinical trials for NEUROENDOCRINE (NE) TUMORS explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE (NE) TUMORS trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE (NE) TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug AUR103 calcium targets Hard-to-Treat neuroendocrine tumors
Disease control Not yet recruitingThis phase 2 study tests a new drug, AUR103 calcium, in 30 adults with advanced neuroendocrine tumors that have worsened after at least one prior treatment. Participants take the drug twice daily until their disease gets worse or side effects become too severe. The main goal is t…
Matched conditions: NEUROENDOCRINE (NE) TUMORS
Phase: PHASE2 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
Learning to manage: new study tests education program for cancer pill side effects
Symptom relief Not yet recruitingThis study looks at whether a special education program helps people with neuroendocrine tumors manage side effects from oral cancer drugs like everolimus and sunitinib. About 100 adults will take part. The goal is to see if the program reduces serious side effects and improves q…
Matched conditions: NEUROENDOCRINE (NE) TUMORS
Sponsor: Hospices Civils de Lyon • Aim: Symptom relief
Last updated Jun 12, 2026 12:04 UTC
-
New study aims to reduce harmful side effects in rare cancer patients
Knowledge-focused Not yet recruitingThis study will follow 1,100 people with advanced neuroendocrine tumors (a rare, slow-growing cancer) to see which treatments or treatment sequences cause the fewest long-term side effects. Researchers will track patients for up to 5 years, recording any side effects that last mo…
Matched conditions: NEUROENDOCRINE (NE) TUMORS
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 11, 2026 12:11 UTC